References
- Zhao S, Lin Y, Xu W, . Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261–265.
- Dang L, White DW, Gross S, . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–744.
- Ward PS, Patel J, Wise DR, . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225–234.
- Ito S, D'Alessio AC, Taranova OV, . Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010;466:1129–1133.
- Xu W, Yang H, Liu Y, . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17–30.
- Pollyea DA, Kohrt HE, Gallegos L, . Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012;26:893–901.
- Pronier E, Almire C, Mokrani H, . Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011;118:2551–2555.
- Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
- Figueroa ME, Abdel-Wahab O, Lu C, . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567.